Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

WuXi PharmaTech and Covance Will Partner in JV

publication date: Jun 25, 2008

WuXi PharmaTech and Covance Inc. signed a Memorandum of Understanding that will create a new joint venture to provide preclinical contract research services in China. WuXi will contribute its new Suzhou lab, currently under construction, and Covance will invest $30 million into the JV. The new facility began construction on September 29, 2007, and it is expected to be on line in 2009. It will offer GLP toxicology, drug metabolism and bioanalytical chemistry services. More details...

Stock Symbols: (NYSE: WX) (NYSE: CVD)



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here